Share on LinkedInShare on LinkedIn

ARTICLE · 26 APRIL 2024

When It Should Be Obvious That "You Don't Know What You Don't Know"—Salix V. Norwich

"The outcome of this issue may yet prove controversial, as both the district court and the Federal Circuit arguably neglected established precedent regarding the doctrine of inherency in ruling...

JapanIntellectual Property

"The outcome of this issue may yet prove controversial, as both the district court and the Federal Circuit arguably neglected established precedent regarding the doctrine of inherency in ruling that the claimed crystalline polymorph invention was obvious. . . ."

In Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd., Alfasigma S.P.A. v. Norwich Pharmaceuticals Inc., Nos. 2022-2153, 2023-1952 (Fed. Cir. April 11, 2024) ("Decision"), the Federal Circuit decided the parties' cross-appeals arising from a bench trial in patent litigation brought by plaintiffs (collectively "Salix") to enjoin approval of Norwich's Abbreviated New Drug Application ("ANDA") to sell a generic version of Salix's branded drug Xifaxan.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from